* Pharmacological Actions:
Azelastine is relatively a selective histamine H1 antagonist and an inhibitor of the release of other mediators from cells (e.g. mast cells) involved in the allergic response. Decreased chemotaxis and eosinophils also has been demonstrated.
For the treatment of itching of the eye associated with allergic conjunctivitis
* Dosage & Administration:
One drop into the affected eye twice daily
– Patients should be advised not to wear a contact lens if their eyes are red.
– AZELAST should not be used to treat contact lens related irritation.
– The preservative in AZELAST, Benzalkonium chloride, may be absorbed by soft contact lenses. Patients who put soft contact lenses and whose eyes are not red, should be instructed to wait at least 10 minutes after using AZELAST before they insert their contact lenses.
– There are no adequate and well controlled studies in pregnant women. AZELAST should be used during pregnancy only if the potential benefits outweigh the potential risks.
– It is not known whether Azelastine is excreted in human milk. Because many drugs are excreted in the human milk, caution should be exercised when AZELAST is administered to a nursing woman.
– Safety and effectiveness in pediatric patients below the age of 3 years have not been established.
AZELAST is for ocular (ophthalmic) use only and not for injection or oral use.
* Manufactured by: El-Kahira Pharm. & Chem. Ind. Co.,
for: EPCI (The Egyptian Co. for Pharmaceutical && Chemical Industries)
AZELASTINE HCL 0.05% (0.5 MG/ML)